The lack of an advisory committee meeting reduces regulatory risk and increases approval probability ahead of the PDUFA date. Traders should monitor for any FDA updates and position ahead of the January 2027 decision, especially given the drug's Breakthrough Therapy status and strong Phase 3 data.
Price Chart
Executive Summary
Praxis Precision Medicines announced that the FDA has accepted its New Drug Application (NDA) for ulixacaltamide HCl to treat essential tremor, with a PDUFA target action date of January 29, 2027. The FDA does not plan to hold an advisory committee meeting, accelerating the review timeline.
Key Facts
- FDA accepted NDA for ulixacaltamide HCl for essential tremor with PDUFA date of January 29, 2027
- No advisory committee meeting planned, indicating streamlined review process
- NDA supported by positive Phase 3 Essential3 trial results showing statistically and clinically significant efficacy
- Ulixacaltamide received Breakthrough Therapy Designation in December 2025
- Drug was generally well tolerated with no drug-related serious adverse events
Financial Impact
Potential first-in-class therapy for essential tremor, a market with high unmet need; commercial launch preparation underway
Risk Factors
- Regulatory delay or rejection despite PDUFA date
- Commercial execution risk post-approval
- Competition from emerging therapies in CNS space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3273225 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $334.79 $282.12 | ▲ +15.73% | ▲ +18.55% | $292.66 (+12.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $247.98 $351.81 | ▲ +41.87% | ▲ +37.47% | $292.66 (+18.02%) |
Jun 2, 2026 17w ago | Press Release | $278.93 $367.85 | ▲ +31.88% | ▲ +29.38% | $292.66 (+4.92%) |
May 7, 2026 21w ago | Press Release | $333.28 $305.51 | ▼ −8.33% | ▼ −12.17% | $292.66 (−12.19%) |
May 4, 2026 21w ago | Press Release | $333.30 $307.75 | ▼ −7.67% | ▼ −10.41% | $292.66 (−12.19%) |
Apr 14, 2026 24w ago | Press Release | $343.60 $333.12 | ▼ −3.05% | ▼ −11.57% | $292.66 (−14.83%) |
Apr 6, 2026 25w ago | Press Release | $310.11 $319.60 | ▲ +3.06% | ▼ −10.41% | $292.66 (−5.63%) |
Mar 30, 2026 26w ago | Press Release | $322.19 $327.79 | ▲ +1.74% | ▼ −10.64% | $292.66 (−9.17%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access